

















































































76Potential Role of Aminoprocalcitonin in the
Pathogenesis of Alzheimer Disease77
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102Increasing evidence suggests that inflammatory responses cause brain atrophy and play a prominent
and early role in the progression of Alzheimer disease. Recent findings show that the neuroendocrine
peptide aminoprocalcitonin (NPCT) plays a critical role in the development of systemic inflammatory
response; however, the presence, possible function, regulation, and mechanisms by which NPCT may be
involved in Alzheimer disease neuropathology remain unknown. We explored the expression of NPCT and
its interaction with amyloid-b (Ab), and proinflammatory and neurogenic effects. By using brain
samples of Alzheimer disease patients and APP/PS1 transgenic mice, we evaluated the potential role of
NPCT on Ab-related pathology. We found that NPCT is expressed in hippocampal and cortical neurons
and Ab-induced up-regulation of NPCT expression. Peripherally administered antibodies against NPCT
decreased microglial activation, decreased circulating levels of proinflammatory cytokines, and pre-
vented Ab-induced neurotoxicity in experimental models of Alzheimer disease. Remarkably, anti-NPTC
therapy resulted in a significant improvement in the behavioral status of APP/PS1 mice. Our results
indicate a central role of NPCT in Alzheimer disease pathogenesis and suggest NPCT as a potential
biomarker and therapeutic target. (Am J Pathol 2016, -: 1e13; http://dx.doi.org/10.1016/
j.ajpath.2016.06.006)Supported by Q4an Instituto de Salud Carlos III (FIS2012/00486) grant, a
FEDER grant, Fundación Investigación Médica Mutua Madrileña grant
2010/0004, Fundación Ramón Areces grant CIVP16A1825, and a
CIBERNED grant (E.C.). E.T. was supported by the Instituto de Salud
Carlos III grant FIS2012/01074, Consejeria de Salud, and Junta de Anda-






















123Alzheimer disease (AD) is the most common form of de-
mentia, accounting for approximately 60% to 90% of all
cases.1 AD is characterized by progressive cognitive and
behavioral impairment, and cerebral deposition of senile
plaques, extracellular accumulation of b-amyloid (Ab)
peptide, and neurofibrillary tangles (intracellular accumu-
lation of hyperphosphorylated tau protein) are unique
neuropathological hallmarks of the disease.2,3 There is a
growing body of evidence linking inflammation and the
pathogenesis of AD.4,5
The brain has been considered to be an immune-privileged
organ, isolated from the peripheral immune system. How-
ever, recent evidence shows that there is a bidirectional
communication between the brain and the peripheral immune
system.5 Indeed, there has been reported to be an association
between systemic inflammation and sepsis, with increased
risk of dementia in a case-control study.6e8 Although clinical
evidence linking the risk of developing AD and systemicstigative Pathology. Published by Elsevier Inc
FLA 5.4.0 DTD  AJPA2403_proof inflammation is still limited and controversial,9 some studies
have shown that elevated peripheral inflammatory markers
are associated with increased risk of dementia,10 suggesting a
positive correlation between systemic inflammation and
neurodegeneration.11 In this context, it has been demon-
strated that patients who have experienced severe infections
show accelerated cognitive decline and this is positively
correlated with peripheral levels of tumor necrosis factor-a
(TNF-a).12 Aminoprocalcitonin (NPCT), a 57eamino acid
polypeptide derived from the N-terminal half of procalcitonin. All rights reserved.
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247(PCT), and encoded by the CALCA gene, was initially
described as a neuroendocrine peptide with bone cell mitogen
activity.13 At physiologic homeostasis, NPCT is expressed in
key brain regions involved in energy homeostasis,14,15 and is
detectable at low levels in blood serum in healthy in-
dividuals.16 However, in sepsis and systemic inflammation,
the CALCA gene is induced by proinflammatory factors, such
as IL-1b, TNF-a, IL-6, and lipopolysaccharides, and cells
throughout the body secrete large amounts of PCT and
NPCT.17 Recent studies suggest that NPCT plays a key role in
the pathogenesis of sepsis and may contribute to the delete-
rious effects of systemic inflammation.
NPCT can elicit a wide range of acute phase responses
that occur in the systemic inflammatory response, when
administered centrally to rats.14,18e20 Elevated plasma levels
of NPCT have been associated with severity of sepsis as
well as with profound feeding, and neuroendocrine and
metabolic effects.21 These effects are blocked by central
administration of a neutralizing antibody to NPCT.
Furthermore, passive or active immunoneutralization of
NPCT significantly improves morbidity and survival, and
attenuates sickness behavior responses in lethal models of
endotoxemia or polymicrobial sepsis induced by cecal
ligation and puncture, even when treatment begins after the
cytokine response has occurred,17,21 suggesting a potential
benefit of immunoneutralization of NPCT in the develop-
ment of sepsis-induced multiorgan dysfunction syndrome.
The protective effects of anti-NPCT are associated with
down-regulation of proinflammatory cytokine expression
and inhibition of inducible transcription factors, such as NF-
kB,17 critical in the transcription of relevant genes and the
generation of proinflammatory cytokines involved in in-
flammatory responses.22
On the basis of all these previous findings, and because
the presence, possible function, regulation, and mechanisms
by which NPCT might be involved in AD neuropathology
remain unknown, we assessed the expression of NPCT,
explored its interaction with the amyloid-b peptide (Ab),
and discussed possible underlying pathway(s) in different
in vitro and in vivo experimental models of AD. We
demonstrate that Ab induces up-expression of NPCT and
that systemic administration of anti-NPCT attenuates neu-
rodegeneration. Our results indicate a central role of NPCT
in the pathogenesis of AD, suggesting it as a potential
diagnostic and therapeutic target for AD.
Materials and Methods
Animal Experiments
Male double transgenic APP/PS1 mice (3 and 12 months
old), B6.Cg-Tg (APPSwe, PSEN1dE9)/J mouse strain,
which expresses human APP (Swedish mutation) and pre-
senilin 1 with a deletion in exon 9, were used from our
inbred colony (Instituto de Investigacion Hospital 12 de
Octubre). Age-matched mice not expressing the transgene2
FLA 5.4.0 DTD  AJPA2403_proowere used as wild-type controls. As a model of toxicity-
induced neuronal death, we injected domoic acid (0.5 mg/
kg, i.p., Tocris Bioscience Q) into adult C57BL/6 male mice
(25 g) to kill hippocampal neurons by excitotoxic damage.23
The degree of impairment was evaluated 7 days after
domoic acid administration, when the maximum level of
deleterious effects of the neurotoxin was reached.23
Experimental Design
Adult male C57BL/6 and APP/PS1 mice were kept under
controlled conditions (temperature, 23C  1C) on a 12-
hour light/dark cycle with food and water ad libitum. Four-
month-old male APP/PS1 and domoic-treated mice were
chronically treated with anti-NPCT polyclonal neutralizing
antibodies to test prevention and amelioration of neuro-
degeneration. Mice were s.c. implanted with osmotic mini-
pumps releasing 0.11 mL/hour for 28 days (model 1004;
Alzet, Palo Alto, CA) prefilled with anti-NPCT (AbD
Serotec Q; 5 mg/mL in phosphate-buffered saline) or control
rabbit nonimmune IgG (Sigma-Aldrich, Madrid, Spain) and
primed in sterile phosphate-buffered saline for 2 hours at
37C before implantation. All solutions were passed
through 0.22-mm pore-size Millipore filters. Implantation
was performed on mice under isoflurane anesthesia. The
Alzet minipumps delivered anti-NPCT at a dose of 500 mg/
kg body weight daily for 28 days. At the end of the treat-
ment, all animals were deeply anesthetized and trans-
cardially perfused with either saline buffer for biochemical
analysis or 4% paraformaldehyde in 0.1 mol/L Qphosphate-
buffered saline for immunohistochemical analysis. All
experiments were performed following the guidelines for
animal care and use promulgated by the Council Directive
2010/63/UE of 22 September 2010.
Human Samples
Cortical and hippocampal samples from human autopsies
were obtained from the Institute of Neuropathology Brain
Bank IDIBELL-Hospital Universitari de Bellvitge (Hospi-
talet de Llobregat, Spain Q), after the approval of the local
ethical committee. The collection of samples conformed to
the relevant regulations, ethical considerations, and legis-
lation, as defined by the European Union and Spain. Sub-
jects were selected on the basis of post-mortem diagnosis of
AD, according to neurofibrillary pathology and b-amyloid
plaques. Control cases were considered those with no
neurological symptoms and with no lesions in the neuro-
pathological examination. The time between death and
processing was between 2 and 12 hours.
Demographic characteristics are shown in Table 1.
Cell Cultures
Primary neuronal cultures from the cerebral cortex and
hippocampus were performed as previously described.24ajp.amjpathol.org - The American Journal of Pathology
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Table 1 Demographics of Brain Human Samples
Case no. Sex Age (years) Postmortem* Diagnosis
1 M 76 6 NL
2 M 61 4 NL
3 M 77 7 NL
4 M 63 3 NL
5 M 75 6 NL
6 M 55 6 NL
7 M 64 5 NL
8 M 57 10 NL
9 M 64 4 NL
10 M 60 9 NL
11 M 85 10 NL
12 F 75 6 NL
13 F 81 4 NL
14 F 64 5 NL
15 F 60 8 NL
16 F 81 5 NL
17 M 84 5 IV/B
18 M 74 5 IV/0
19 M 73 3 IV/0
20 M 75 11 V/B
21 M 82 4 V/C
22 M 77 10 V/C
23 M 61 8 V/C
24 M 79 7 V/C
25 M 93 3 V/C
26 M 63 2 VI/C
27 F 85 4 IV/0
28 F 86 10 IV/0
29 F 88 4 IV/0
30 F 74 4 IV/0
31 F 74 5 V/C
32 F 81 5 V/C
33 F 85 5 V/C
34 F 86 12 VI/C
35 F 56 7 VI/C
36 F 80 5 VI/C
37 F 63 10 VI/C
*Postmortem delay in hours.
F, female; M, male; NL, no lesion; IV-VI/0-C, Alzheimer diseaseerelated




























































































































371Primary cortical and hippocampal neurons were obtained
from Wistar rat embryos on prenatal day 17 (E17). Cerebral
cortex and hippocampus was dissected, incubated for 5
minutes in Neurobasal medium (Gibco) at 37C and me-
chanically dissociated for 5 minutes, and finally centrifuged
at 210  g for 5 minutes at 21C. The cells were suspended
in Neurobasal medium (Gibco) supplemented with B27
(Gibco), 2 mmol/L glutamine, 100 U/mL penicillin, 100 mg/
mL streptomycin, and 0.25 mg/mL amphotericin B. Cul-
tures were kept at 37C in a humidified atmosphere con-
taining 5% CO2 for 7 days before experimentation. Then,
cultures were incubated in fresh medium with or without 10
mmol/L oligomeric Ab42, 1 mmol/L pyrrolidine dithio-
carbomate (Sigma), and 2.5, 25, or 50 mg/mL anti-NPCT for
48 hours. Ab42 was dissolved in 0.1 mol/L acetic acid, andThe American Journal of Pathology - ajp.amjpathol.org
FLA 5.4.0 DTD  AJPA2403_proof then was diluted in sterile distilled water as previously
reported.25
Immunoassays
Western-blotting NPCT assays were performed as described
previously.19 Proteins were isolated from brain tissue or cell
cultures by standard methods. Briefly, brain tissues were
homogenized in tris-buffered saline (50 mmol/L Tris-HCl,
pH 7.4, 5 mmol/L EDTA, and 2% SDS) containing a
mixture of protease inhibitors. Homogenates were centri-
fuged, and supernatants were run on 4% to 20% SDS-PAGE
under reducing conditions. Proteins were transferred to
polyvinylidene difluoride membranes (GE Healthcare Q) and
incubated with the specific antibodies. Primary antibodies
used were mouse anti-NPCT (1:500; Novus Biologicals Q)
and mouse antieb-actin (1:10,000; Millipore Q). Secondary
horseradish peroxidaseeconjugated goat anti-mouse was
used (1:20,000; Bio-Rad Laboratories Q).
Ab sandwich enzyme-linked immunosorbent assays
(ELISAs) were performed as previously described.26 For
detection of human Ab, we used a human-specific antibody
to Ab (6E10; Sigma) in the first layer and anti-Ab40 or anti-
Ab42 (Calbiochem Q) in the top layer.
Activation of NF-kB p65 was determined in neuronal
cultures by ELISA using a commercially available ELISA
kit (Active Motif), as described.27
Cell viability within primary neuronal cultures treated
with or without 10 mmol/L Ab42, and 2.5, 25, or 50 mg/mL
anti-NPCT, was assessed using Cell Counting Kit-8 (CCK-8
assay; Sigma, St. Louis, MO).
RNA was extracted from mouse cerebral cortex, and
TaqMan qRT-PCR Qassays for each gene were performed as
previously described.28 Probes included members of proin-
flammatory and anti-inflammatory cytokines, such as IL-6,
members of the TNF-a family, IL-10 and receptors, and
transforming growth factor-b family.
Plasma samples from mice were centrifuged at 30,000 
g for 20 minutes, and stored at 80C until cytokine
determination. Murine IL-1b, IL-6, TNF-a, and macrophage
inflammatory protein-2 levels in supernatants were
measured using a Luminex customized rat 4-plex cytokine
assay kit, according to the manufacturer’s instructions
(Procarta Cytokine Assay Service; Affymetrix, Santa Clara,
CA). Data were analyzed using the Luminex QManager
software. The detection limit was 1.2 pg/mL.
Immunohistochemical Studies
Animal Tissue
Fixed brains were cut on a vibratome (Leica Microsystems Q)
at 50 mm, and tissue sections were collected in cold PB Q0.1
mol/L, and incubated overnight with primary antibodies at
4C. All primary antibodies were diluted in PB 0.1 mol/L
containing 0.5% bovine serum albumin and 0.5% Triton X-
100. To detect Ab deposits, brain sections from APP/PS13
372

















































































Figure 1 NPCT expression in 12-month-old APP/
PS1 mice. Microphotographs of cerebral cortex (A)
and hippocampus (B) showing intense NPCT immu-
nostaining of cells in APP/PS1 mice compared with
littermate control mice. C: Representative Western
blot of NPCT levels in cortical samples from APP/PS1
and wild-type mice. D: Densitometric quantification
of the NPCT protein levels in cortical samples from
APP/PS1 mice, and wild-type mice. E: Representa-
tive Western blot showing higher NPCT levels in
hippocampal samples from APP/PS1 and wild-type
mice. F: Densitometric quantification of the NPCT
protein levels in hippocampal samples from APP/PS1
mice, and wild-type (WT) mice. G: Confocal images
showing that NPCT (red) and NeuN (green) coloc-
alize abundantly in hippocampal neuronal cells. H:
Double immunofluorescence assays from cortical
sections of APP/PS1 mice showing that NPCT
immunostained (green) appear to have an enhanced
association with the Ab-immunopositive material
(red). Data
Q38
are expressed as means  SEM (D and F).
n Z 6 (AeF and H). Q39*P < 0.05, Student’s t-test.









































































































































495mice were preincubated with 88% formic acid, and immu-
nostained as previously described.26 To detect NPCT
expression, brain sections from APP/PS1 mice were incu-
bated with anti-NPCT antibody, as previously described.19
Primary antibodies used were as follows: mouse anti-
NPCT (1:300; Novus Biologicals), mouse anti-NeuN
(1:1000; Millipore), rabbit anti-Ab (1:500; Millipore), and
rabbit anti-Iba1 (1:500; Wako). Primary antibody staining
was revealed using the avidin-biotin complex method
(VECTASTAIN Elite ABC Kit; Vector Laboratories) and
diaminobenzidene chromogenic reaction (Vector Labora-
tories), or fluorescence-conjugated donkey anti-mouse IgG
488 (1:1000; FluoProbes, Interchim), and Texas Red goat
anti-rabbit IgG antibody (1:1000; Jackson Immunoresearch,
West Grove).
Iba1 fluorescence intensities were evaluated in the
selected brain regions: between bregma 0.7 and 4.3 mm4
FLA 5.4.0 DTD  AJPA2403_proo(cerebral cortex) and bregma 2.0 and 4.3 mm (hip-
pocampus), respectively. All images were taken by the
same blinded experimenter Qusing a Zeiss LSM 510 Meta
scanning laser confocal microscope (Carl Zeiss Micro-
imaging GmbH) Qwith a 40 objective. Selected Iba1þ
areas were analyzed with ImageJ software Q(NIH,
Bethesda, MD), and data were presented as the percentage
of fluorescence intensity, and as the number of Iba1þ
proliferative areas.
One additional series was used for Nissl staining with
Cresyl Violet (Acros Organics Q). To estimate the number of
neurons in the hippocampal hilus, Nissl-positive cells were
counted in a one-in-six series of sections under a light mi-
croscope (Carl Zeiss Microimaging GmbH) at 40 magni-
fication, as previously described.29
Fluoro-Jade B (Histochem, Jefferson, AR) staining was
performed to stain degenerated neurons as describedajp.amjpathol.org - The American Journal of Pathology
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595previously.30 For stereological analysis, Fluoro-Jadee-
positive cells were counted in a one-in-six series of sections
(300 mm apart) using a Zeiss LSM 510 Meta scanning laser
confocal microscope with a 40 objective (Leica)
throughout the rostral-septal half of the dentate gyrus (from
the rostral most extreme of the hippocampus, at bregma
2.0 mm, to the caudal end, at bregma 4.3 mm). The
same areas and number of sections were studied for all of
the animals and all of the experimental groups. We
considered as Fluoro-Jadeþ those cells completely filled
with fluorescent marker. We estimated the cell number of
Fluoro-Jadeþ in the dentate gyrus, and expressed it as the
number of positive cells per tissue section. Morphometrical
analysis was performed using ImageJ.
Cell Culture
For immunocytochemistry, primary neurons were cultured
on poly-L-lysineecoated glass slides, and treated with 10
mmol/L oligomeric Ab42 for 48 hours, after which they were
fixed in 4% paraformaldehyde for 1 hour. Then, cells were
incubated with a mouse anti-NPCT (1:500; Novus
Biologicals), and anti-NeuN (1:1000; Millipore). All
primary antibodies were diluted in PB 0.1 mol/L containing
0.5% bovine serum albumin and 0.5% Triton X-100. Sec-
ondary antibodies: as above. DAPI (1:10,000; Sigma) was
used to stain nuclei.
Behavioral Testing
After adaptation to human handling, behavioral tests were
conducted in APP/PS1 and wild-type non-transgenic mice,
treated with anti-NPCT or vehicle pumps, as previously
described.31 The open field was performed in a box with a



















Figure 2 NPCT expression in Alzheimer disease (AD) patients. Microphotogra
munostaining of cells in AD brain sections compared with control human samples
and control samples. Densitometric quantification of the NPCT protein levels in co
Western blot of NPCT levels in hippocampal samples from AD samples. Densitometr
group, and control human group. Data are expressed as means  SEM (B and D).
*P < 0.05, Student’s t-test. Scale bars Z 20 mm (A and C).
The American Journal of Pathology - ajp.amjpathol.org
FLA 5.4.0 DTD  AJPA2403_proof central area with a 25 cm  25 cm surface. Ambulatory
counts were recorded for a 5-minute period for 3 days.
Values were expressed as total number of entrances and
total time spent in the central area. Ratio was defined as the
time spent in the central area over the total time spent in
both central (c) and peripheral (p) areas: [tc/(tc þ tp)].
In the elevated plus maze test, the time spent in the
different compartments of the maze (open and closed arms),
and the number of entrances into the arms, was measured.
The open/total arm entrances and duration ratios were then
calculated.
Statistical Analysis
Data are expressed as means  SEM. Differences between
groups were analyzed with one-way analysis of variance
followed by Mann-Whitney post hoc test. Post hoc com-
parisons between two groups were performed with Student’s
t-test. All calculations were made using SPSS Qsoftware
version 15.0. Statistical significance was set at P < 0.05.
Results
NPCT Expression in APP/PS1 Mice and AD Patients
We evaluated NPCT expression in the brains of 3- and
12-month-old APP/PS1 mice using immunohistochemical
analysis. We found increased NPCT immunoreactivity
both in cortical (Figure 1A) and hippocampal (Figure 1B)
cells on sections from 12-month-old APP/PS1 mice
compared to age-matched control mice. Further supporting
the immunohistochemical data, Western blot analyses
were performed. Although NPCT levels were significantly
unchanged in cortical samples (Figure 1, C and D), ourControl                  
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Q40phs of cerebral cortex (A) and hippocampus (C) showing intense NPCT im-
. B: Representative Western blot of NPCT levels in cortical samples from AD
rtical samples from AD group, and control human group. D: Representative
ic quantification of the NPCT protein levels in hippocampal samples from AD


































































































































706findings indicated increased NPCT expression in hippo-
campus from APP/PS1 mice compared to control mice
(Figure 1, E and F). We also tested NPCT expression in
3-month-old APP/PS1 mice. Although there was a trend
toward increase in the expression of NPCT protein, no
significant changes were detected in either hippocampal or
cortical samples (data not shown). Double-
immunofluorescence assays demonstrated that NPCT
was mainly expressed in neurons (Figure 1G), as
demonstrated using NeuN as a specific neuronal marker.
But we also found NPCT immunolabeling in glial cells,
including astrocytes (Supplemental Figure S1A), and
microglia (Supplemental Figure S1B). Immunoreactivity
of NPCT concentrated around the Abþ plaques was
evident, using double immunostaining, in the cerebral
frontal cortex of APP/PS1 mice (Figure 1H). To exclude
cross-reactivity of NPCT with Ab, we performed an Ab
ELISA assay replacing the capture antibody of ELISA
system, mouse anti-Ab clone 6E10 (Sigma) with an anti-
body against NPCT, mouse anti-NPCT (Novus Bi-
ologicals). We did not find any cross-reactive signal of


















































































FLA 5.4.0 DTD  AJPA2403_prooWe next determined NPCT expression in cerebral
cortex and hippocampus of human tissue (Figure 2).
Levels of NPCT measured by immunohistochemistry and
Western blotting were dramatically enhanced in both
cortical (Figure 2, A and B) and hippocampal (Figure 2 Q,
C and D) samples in AD patients compared with healthy
subjects.
To examine whether Ab modulates NPCT expression in
neuronal cells, primary neuronal cultures were treated with
10 mmol/L oligomeric Ab42 for 48 hours. We observed a
marked increase in NPCT expression induced by Ab42
exposure in cultured neurons (Figure 3A). Quantification of
the NPCT immunoreactivity labeling cultured neurons
confirmed this increased NPCT expression (Figure 3B).
Similar Ab42-induced overexpression of NPCT was also
observed in astrocyte cultures (Supplemental Figure S1C).
As expected,32,33 we found that Ab42 activates NF-kB.
Treatment with oligomeric 10 mmol/L Ab42 resulted in a
significant increase in NF-kB DNA-binding activity in
neuronal cultures 48 hours (Figure 3C) after treatment
addition. This Ab42-induced effect on NF-kB activation was
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Figure 3 Amyloid b (Ab)-induced NPCT expression
in neuronal cell cultures. A: Fluorescent photomicro-
graphs of neurons cultured without or with 10 mmol/L
Ab42 for 48 hours. Labeling of NeuN (red), NPCT
(green), and DAPI-stained nuclei (blue). B: Quantifi-
cation shows significantly higher NPCT immunoreac-
tivity in neurons incubated with Ab42. Student’s t-test
was used. C: Ab42 (10 mmol/L) treatment increases NF-
kB DNA-binding activity in neuronal cultures 48 hours,
whereas this effect is blocked by adding 1 mmol/L
pyrrolidine dithiocarbomate (PDTC), a selective in-
hibitor of NF-kB. One-way analysis of variance, fol-
lowed by Mann-Whitney post hoc test, was used.
Representative Western blot (D) and densitometric (E)
quantification shows that the inhibition of NF-kB
pathway with 1 mmol/L PDTC clearly abrogates Ab42-
induced NPCT expression. One-way analysis of vari-
ance, followed by Mann-Whitney post hoc test, was
used. F: Anti-NPCT treatment using several concen-
trations (2.5, 25, and 50 mg/mL) abrogates 10 mmol/L
Ab42-induced decreased cell viability measured 48
hours after treatment in neuronal cell cultures. One-
way analysis of variance, followed by Mann-Whitney
post hoc test, was used. Data are expressed as
means  SEM (BeF). nZ 3 Q41independent experiments
(F). Q42*P < 0.05, **P < 0.01.



























































































































813a selective inhibitor of NF-kB (Figure 3C). Using pyrroli-
dine dithiocarbomate, we showed that the inhibition of
NF-kB pathway clearly abrogated the effect of Ab42 on
NPCT expression measured by Western blotting (Figure 3,
D and E). Hence, the results obtained herein suggest that Ab
modulates NPCT expression through NF-kB signaling.Figure 4 Immunoneutralization of NPCT diminishes microglial activation in 5-m
hippocampal (B) sections of APP/PS1, and wild-type mice. Labeling of Iba1 (red),
higher Iba1 immunoreactivity in APP/PS1 mice. Anti-NPCT treatment significantly
(D) in APP/PS1 mice. Blood levels of IL-1b (E), IL-6 (F), tumor necrosis factor (T
APP/PS1mice compared with control mice, whereas these values are significa
means  SEM (CeH). nZ 6 vehicle-treated and antieNPCT-treated wild-type mice
and B), vehicle-treated APP/PS1 mice (C and D), and APP/PS1 mice (EeH); n Z 8
mice (C and D), and anti-NPCT mice (EeH). *P < 0.05, one-way analysis of varian
WT, wild type.
The American Journal of Pathology - ajp.amjpathol.org
FLA 5.4.0 DTD  AJPA2403_proof Immunoneutralization of NPCT Reduces Ab-Induced
Cytotoxicity in Neuronal Cell Cultures
To investigate whether NPCT was able to regulate Ab-
induced cytotoxicity, we decided to study the influence of
anti-NPCT on the cell death induced by Ab42 exposure. Toonth-old APP/PS1 mice. Fluorescent photomicrographs of cortical (A), and
and DAPI-stained nuclei (blue). C and D: Quantification shows significantly
decreases Iba1 staining in the cerebral cortex (C), but not in hippocampus
Q43NF)-a (G), and macrophage inflammatory protein (MIP)-2 (H) are higher in
ntly reduced 1 month after anti-NPCT treatment. Data are expressed as
(A and B) and control mice (EeH); nZ 7 vehicle-treated APP/PS1 mice (A
antieNPCT-treated wild-type mice (A and B), antieNPCT-treated APP/PS1






























































Table 2 Cortical mRNA Expression of Selected Cytokine-Related
Genes Involved in the Inflammatory Response in WT and APP/PS1
Mice Aged 5 Months
Variable WT APP/PS1
Proinflammatory cytokines
Il-1b 1.05  0.15 1.09  0.12
Hematopoietins
Il-6 1.01  0.08 1.14  0.11
Il-6st 1.00  0.05 0.85  0.06
TNF family
TNF-a 1.09  0.25 0.90  0.21
TNFrsf1a 1.01  0.05 0.89  0.10
Anti-inflammatory cytokines
IL-10 family
Il-10ra 1.00  0.02 0.90  0.09
Il-10rb 1.01  0.08 0.96  0.11
TGF-b family
TGF-b1 1.01  0.06 0.97  0.14
TGF-b2 1.01  0.08 0.97  0.12
Data are represented as the means  SEM.





























































































































991test this hypothesis, anti-NPCT, and Ab42 proteins were
added to primary neuronal cultures, and CCK-8 cytotoxicity
assay was used for determination of cell viability. As we
expected, a significantly reduced cell viability was detected
48 hours after 10 mmol/L Ab42 treatment, whereas this effect
was completely blocked by anti-NPCT treatment using
several concentrations (2.5, 25, and 50 mg/mL) (Figure 3F).
Immunoneutralization of NPCT Protects against
Domoic-Induced Neuronal Loss
Because neuron loss in APP/PS1 mice is modest, and occurs
only in late ages, at approximately 17 months,34 we decided
to investigate potential neuroprotective effects mediated by
NPCT in a good accepted model of neurodegeneration
associated with neuronal death. Thus, we tested whether
administration of anti-NPCT would also block domoic
acideinduced neuronal death. Domoic acid induced marked
neuronal damage (Supplemental Figure S2). In domoic
acidetreated mice, Nissl-stained neurons of the dentate hilus
of the hippocampus were reduced, whereas treatment with
anti-NPCT prevented this lesion-induced neuronal death
(Supplemental Figure S2A). Stereological quantification
revealed that injection of domoic acid in mice resulted in the
loss of >50% of neurons in hippocampal hilus, compared to
control mice (P< 0.05) (Supplemental Figure S2B), whereas
treatment with anti-NPCT significantly prevented lesion-
induced neuronal death (Supplemental Figure S2B).
Immunoneutralization of NPCT Modulates
Inflammatory Responses in APP/PS1 Mice
Activated microglia was visualized via confocal microscopy
using brain sections immunostained with the microglial
marker Iba1 (Figure 4). The overall Iba1 fluorescence in-
tensities were totally in the cerebral cortex (Figure 4, A and
C), or partially decreased in hippocampus (Figure 4, B and
D) in 5-month-old APP/PS1 mice treated with anti-NPCT.
Even when microglial activation was enhanced in these
APP/PS1 mice, quantitative RT-PCR analysis showed
that mRNA expression of selected cytokine-related genes
involved in the inflammatory response did not differ be-
tween wild-type and APP/PS1 mice at the age of 5
months (at the end of experiment) (Table 2). These
findings are in accordance with recent data comparing
wild-type and APP/PS1 mice at different ages, and
showing increased mRNA expression of the assessed
cytokines and mediators in APP/PS1 mice aged 12
months but not at earlier stages when compared with
wild-type littermates.28 The present findings do not rule
out modifications in the expression of mediators at protein
level but merely indicate that mRNA cytokine expression
in wild-type and APP/PS1 mice is a much regulated
mechanism.
Because recent studies have revealed a critical role of NPCT
in the regulation of inflammatory responses in peripheral8
FLA 5.4.0 DTD  AJPA2403_proosystems,17,21 and because AD is considered as a systemic
disorder, we evaluated whether NPCT contributes to Ab
neurotoxicity and AD pathology by regulating the systemic
inflammatory response. Plasma levels of IL-1b, IL-6, TNF-a,
and macrophage inflammatory protein-2 increased 18.8-, 3.5-,
2.5-, and 4.2-fold, respectively, in APP/PS1 mice compared
with wild-type control mice (Figure 4, EeH). However, anti-
NPCT treatment decreased the plasma levels of IL-1b, IL-6,
TNF-a, and macrophage inflammatory protein-2 by 81%,
64%,60%, and64%, respectively, inAPP/PS1mice (Figure4).Immunoneutralization of NPCT Diminishes
Neurodegeneration in APP/PS1 Mice
Although Fluoro-Jade B can be used to label activated
glial cells that are abundant in the brain of these AD
transgenic mice, it is also known as a high-affinity fluo-
rescent marker for the localization of neuronal degenera-
tion during acute neuronal distress. Widespread Fluoro-
Jade Bepositive neurons were detected in the cerebral
cortex (Figure 5A) and in the hippocampus (Figure 5B) of
APP/PS1 mice. Although Fluoro-Jade B staining was
unchanged in cerebral cortex of APP/PS1 mice after anti-
NPCT administration (Figure 5A), we observed that
Fluoro-Jade B labeling in the dentate gyrus of APP/PS1
mice decreased significantly after treatment with anti-
NPCT administration, as compared with vehicle-treated
APP/PS1 mice (Figure 5B). Stereological analysis of
multiple stained sections revealed that the number of
Fluoro-Jade Bepositive neurodegenerative neurons was
significantly reduced in antieNPCT-treated APP/PS1
mice compared with vehicle-treated APP/PS1 mice
(P < 0.05) (Figure 5C).ajp.amjpathol.org - The American Journal of Pathology
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Figure 5 Immunoneutralization of NPCT diminishes neurodegeneration in APP/PS1 mice.
Photomicrographs show fluorescent Fluoro-Jade B staining in the cerebral cortex (A) and the
hippocampus (B) of APP/PS1 mice, and wild-type mice. C: The histogram shows the number of
Fluoro-Jade Bepositive cells in APP/PS1, and control mice. Stereological analysis reveals a
significant reduction in the number of neurodegenerative cells in the hippocampus after 1
month of anti-NPCT treatment. Data are expressed as means  SEM (C Q45). n Z 6 vehicle-treated
and antieNPCT-treated wild-type mice (A and B) and vehicle-treated and antieNPCT-treated
control mice (C); n Z 7 vehicle-treated APP/PS1 mice (A and B) and vehicle-treated APP/PS1
mice (C); n Z 8 antieNPCT-treated APP/PS1 mice (AeC). *P < 0.05, **P < 0.01, one-way
analysis of variance, followed by Mann-Whitney post hoc test. Scale bars Z 20 mm (A and




























































































































1115Immunoneutralization of NPCT Alleviates Behavioral
Impairment in APP/PS1 Mice
To determine whether NPCT affected cognitive, explor-
atory, and anxiety-associated behavior, we examined the
performance of APP/PS1 mice treated with anti-NPCT in
several tests, as previously described.31 In the open field,
where emotional states were able to be examined, vehicle-
treated APP/PS1 mice spent more time in the center area,
suggesting disinhibitory tendency, an anxiety-related
phenotype, a type of emotional disturbance characteristic
of APP/PS1 mice (Figure 6A). However, the behavioral
pattern exhibited in antieNPCT-treated APP/PS1 mice was
similar to that observed in wild-type mice (Figure 6A),
suggesting that immunoneutralization of NPCT might pre-
vent emotional disturbances. Results in the elevated plus
maze, a well-established paradigm to detect both anxiolytic-
and axiogenic-like behavior, are in agreement with this
hypothesis. AntieNPCT-treated APP/PS1 mice spent
significantly less time in the open arms than vehicle-treated
APP/PS1 mice, expressed as entry ratio, and similar to what
was observed in wild-type mice (Figure 6B).The American Journal of Pathology - ajp.amjpathol.org
FLA 5.4.0 DTD  AJPA2403_proof Discussion
Our data suggest that brain amyloidosis is linked to
increased brain expression of NPCT. To our knowledge, this
is the first report of the up-regulation of NPCT in cerebral
cortex and hippocampal samples of AD patients and APP/
PS1 mice. High concentrations of NPCT have been asso-
ciated with inflammation, infection, and sepsis.17,21 The
inflammatory release of NPCT can be induced either
directly, via microbial toxins (eg, endotoxin), or indirectly,
via proinflammatory cytokines such as IL-1b, IL-6, or TNF-
a.35,36 These cytokines play a key role in neuro-
inflammatory processes, and their overproduction in the
central nervous system has been implicated as a key
contributor to pathophysiology progression in AD.37 We
herein reported that NPCT expression was increased in 12-
month-old APP/PS1 mice, whereas it was unchanged in
younger mice. Because cytokines are elevated in APP/PS1
mice aged 12 months but not at earlier stages, and Ab in-
duces up-regulation of IL-1b, IL-6, and TNF-a,38e40 we
hypothesized that Ab was involved in the enhancement
of NPCT expression through stimulation of these9
1116































































Figure 6 Immunoneutralization of NPCT alleviates behavioral impair-
ment in APP/PS1mice. A:Q46 In the open field, APP/PS1 mice spend more time
in central zone than wild-type (WT) mice, whereas antieNPCT-treated APP/
PS1 mice exhibit similar behavior to that observed in control mice groups.
B: In the elevated plus maze, antieNPCT-treated APP/PS1 mice spend
significantly less time in the open arms than vehicle-treated APP/PS1 mice,
expressed as entry ratio, and similar to what is observed in wild-type mice.
Data are expressed as means  SEM (A and B). n Z 7 (A and B, APP/PS1
mice); nZ 6 (A, WT and control mice); nZ 8 (A and B, antieNPCT-treated
APP/PS1 mice). *P < 0.05, one-way analysis of variance, followed by




























































































































1239proinflammatory cytokines. The results of our experiments
also suggest that NPCT expression is induced by Ab via
NF-kB activation, an effect and signaling pathway similar to
that observed in the modulation of proinflammatory cyto-
kines. In agreement with previous data,32,33,41 we found that
Ab42 activates NF-kB pathway modulating downstream
cytokine production. Although the precise mechanism
involved in Ab-induced NPCT modulation is not
completely understood, our findings suggest that selective
inhibition of NF-kB pathway suppressed Ab42-induced up-
regulation of NPCT.10
FLA 5.4.0 DTD  AJPA2403_prooRecent research indicates that NPCT is actively involved
in the systemic inflammatory response. It has been shown
that NPCT-induced cytokine production is mediated by
NF-kB activation42 and that immunoneutralization of
endogenous NPCT with antibodies that are reactive to
NPCT significantly improves survival in two different
models of lethal sepsis via inhibition of NF-kB activation
and cytokine production.17,21 Our results indicate that
treatment with anti-NPCT prevents cytokine production and
attenuated Ab-induced cytotoxicity. These findings suggest
that the NPCT-mediated neuroprotective effect against AD
appears to be associated, at least in part, with blocking
NF-kB activation and likely with down-regulating cytokine
expression. Although clinical evidence linking the risk of
developing AD and systemic inflammation is still limited
and controversial,9 some observational studies have shown
that elevated concentrations of peripheral inflammatory
markers are associated with increased risk of overall de-
mentia,10,11,43 suggesting a positive correlation between
systemic inflammation and neurodegeneration. Moreover,
increased serum proinflammatory cytokines, including IL-6,
and TNF-a, are associated with AD and its cognitive
deterioration.5
Neuroinflammation has been implicated in Ab-induced
neuronal death,44,45 although its precise role in the devel-
opment and progression of AD is not completely clear. Ab
is a potent and direct neurotoxic agent, and it induces a
cascade of cellular mechanisms, including up-regulation of
inflammatory cytokines that may play an important role in
neuronal death. Multiple preclinical and clinical studies
support the causative role of Ab in the pathogenesis of
AD.46 Consequently, Ab leads to neurodegeneration and
progressive loss of neurons in specific brain regions, some
of them involved in cognitive functions, such as hippo-
campus. In this study, we found neuroprotective effects
against Ab-induced toxicity after immunoneutralization
with anti-NPCT. We also used domoic acideinduced
excitotoxic damage as a model of experimental neuro-
degeneration23,29 to investigate whether anti-NPCT treat-
ment offers protection against other types of neuronal
insults. Excitotoxicity contributes to a variety of disorders in
the central nervous system, with the subsequent degenera-
tion of selective populations of neurons in the brain, and
associated with cytokines and other inflammatory molecules
secreted by activated glia cells. Some studies have shown
that peripheral or central administration of domoic acid in-
duces hippocampal-derived seizures and extensive neuronal
damage to hippocampal neurons.47,48 Our present findings
suggest that down-regulating NPCT protects hippocampal
neurons against domoic acidemediated excitotoxicity,
probably down-regulating inflammatory cytokine secretion,
opening new potential applications in other neurodegener-
ative disorders.
Noncognitive symptoms, such as agitation, aggression,
depression, and psychosis, in addition to progressive
cognitive deterioration, are often observed in dementedajp.amjpathol.org - The American Journal of Pathology
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1363patients, including those with AD. These neuropsycho-
logical symptoms often exhibit sudden onset and are
triggered by an acute change in the patient’s physical
condition, such as infection,5 suggesting that inflamma-
tion may play an important role in the pathogenesis
underlying these dementia-associated behavioral distur-
bances. More important, severe neuropsychological
symptoms triggered by peripheral infection can develop
without signs of sepsis.49 On the basis of these reports, it
has been hypothesized that systemic infections may
contribute to the pathogenesis or pathophysiology of AD,
and pathogen-induced chronic infection should be
considered a risk factor for sporadic AD.50 In addition, we
agree with the idea that early intervention against infec-
tion may delay or even prevent the future development
of AD.
In animal models of neurodegeneration, systemic
inflammation results in the development of sickness
behavior and neuronal cell loss.51 In our study, APP/PS1
mice displayed significantly greater exploratory rearing,
suggesting anxiety, one of the main characteristic symptoms
in AD. However, treatment with anti-NPCT seemed to
prevent emotional disturbances in transgenic AD mice. Our
study supports the hypothesis that there is a clear cause-and-
effect relationship between activated systemic inflammation
and the development of neuropsychiatric symptoms in AD,
although a mechanistic explanation for the relationship has
not been completely formulated (Supplemental Figure S3).
The present study has shown increased expression of NPCT
in AD brain of mouse models and patients. In addition, this
Ab-induced NPCT stimulation has been described in
neuronal cells, and involved the activation of the NF-kB
pathway. Immunoneutralization of NPCT significantly
attenuated the Ab-induced cytotoxicity, with a significantly
increased survival rate in neuronal cultures, but also an
important reduction in hippocampal neurodegeneration, and
behavioral impairments in APP/PS1 mice. The beneficial
effect of anti-NPCT treatment in these transgenic mice also
involved inhibition of peripheral proinflammatory cytokine
production. Recently, the significance of systemic inflam-
mation in the etiology of AD has become so prevalent that
Krstic and Knuesel coined the term inflammation hypothesis
of AD.52 Briefly, they hypothesize that chronic inflamma-
tion dysregulates the mechanism for clearing misfolded or
damaged neuronal proteins in aging brains that lead to
accumulation of APP and synaptic dysfunction. Concomi-
tantly, chronic inflammation also primes microglia to a
hyperreactive state that impairs dystrophic neurite clearance,
which, in turn, generates a neurotoxic proinflammatory
environment that affects neighboring neurons. Elevated
levels of inflammatory proteins, notably C-reactive protein
and IL-6, have been reported in the plasma of AD patients 5
years before the clinical onset of dementia as compared with
age-matched individuals.53 We support the hypothesis by
which early-life or life-long systemic inflammation may
trigger microglia priming in the central nervous system.11The American Journal of Pathology - ajp.amjpathol.org
FLA 5.4.0 DTD  AJPA2403_proof Later in life, the primed microglia may become hypersen-
sitive, maintain a prolonged activation state, and produce
elevated levels of inflammatory mediators that may poten-
tially exacerbate AD neuropathology and promote neuro-
degeneration. Thus, in our experimental model using
5-month-old APP/PS1, early up-regulation of proin-
flammatory cytokines is first detected in blood, when brain
cytokine release from microglial reactivity has yet to begin,
as proposed by Heneka et al,11 suggesting that microglial
cells in the brain may be exacerbated by systemic
inflammation.
In summary, our results suggest that anti-NPCT immu-
notherapy ameliorates behavioral deficits, and reduces in-
flammatory responses and cell death in the brain. Taken
together, these findings demonstrate, for the first time, that
anti-NPCT may have the potential for attenuating Ab-
induced cognitive deficits by reducing inflammatory re-
sponses and neurodegeneration, which may add to new
evidence for anti-inflammatory properties of anti-NPCT in
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1694Supplemental Figure S1 NPCT expression in glial cells. Confocal images showing the colocalization of NPCTþ (green) with glial fibrillary acidic protein
(GFAP)þ (red) astrocytes (A), and Iba 1þ (red) in microglia (B). C: Fluorescent photomicrographs of astrocytes cultured without or with 10 mmol/L Ab42 for 48
hours. Labeling of GFAP (red), NPCT (green), and DAPI-stained nuclei (blue). Scale bars Z 20 mm (A and B).
Supplemental Figure S2 Immunoneutralization of NPCT protects against domoic-induced neuronal loss. A: Representative Nissl-stained sections of the
hippocampal dentate hilus from corresponding experimental groups. B: Stereological quantification reveals that mice injected with domoic acid show a
significant decrease of Nissl-stained cells, whereas 1 month after treatment with anti-NPCT counteracts this negative effect. Data are expressed as
means  SEM (). n Z 6 to 8 animals per group (A); n Z 6 mice injected with domoic acid (B); n Z 8 mice treated with anti-NPCT (B). *P < 0.05, one-way
analysis of variance, followed by Mann-Whitney post hoc test. Scale bars Z 20 mm. DG, dentate gyrus.
Supplemental Figure S3 Proposed neuropathological schematic pathways. Cerebral accumulation of amyloid plaques leads to neurodegeneration in the
Alzheimer disease (AD) brain, which causes progressive cognitive dysfunction. These symptoms can be triggered by peripheral infection or inflammation,
suggesting an important contribution of peripheral inflammation. Brain amyloid-b (Ab) up-regulates NPCT expression to induce proinflammatory cytokines,
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